JP2006516094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516094A5 JP2006516094A5 JP2004551756A JP2004551756A JP2006516094A5 JP 2006516094 A5 JP2006516094 A5 JP 2006516094A5 JP 2004551756 A JP2004551756 A JP 2004551756A JP 2004551756 A JP2004551756 A JP 2004551756A JP 2006516094 A5 JP2006516094 A5 JP 2006516094A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- disease
- mammal
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 35
- 241000124008 Mammalia Species 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 12
- 108090001123 antibodies Proteins 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 210000001519 tissues Anatomy 0.000 claims 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 230000003042 antagnostic Effects 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 230000004936 stimulating Effects 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 229920001405 Coding region Polymers 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 208000004275 Demyelinating Disease Diseases 0.000 claims 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 1
- 208000007475 Hemolytic Anemia Diseases 0.000 claims 1
- 208000005252 Hepatitis A Diseases 0.000 claims 1
- 206010019780 Hepatitis infectious Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010021425 Immune system disease Diseases 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000004358 Polyneuropathy Diseases 0.000 claims 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims 1
- 206010038428 Renal disease Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 208000006045 Spondylarthropathy Diseases 0.000 claims 1
- 206010052775 Spondyloarthropathy Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010043778 Thyroiditis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047931 Whipple's disease Diseases 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000006322 bullous skin disease Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 201000007192 granulomatous hepatitis Diseases 0.000 claims 1
- 201000010229 hepatobiliary disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000005505 measles Diseases 0.000 claims 1
- 230000003278 mimic Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 201000002481 myositis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Claims (26)
- (a)図1ないし1477(配列番号1ないし1477)のいずれか1つに示すヌクレオチド配列;又は
(b)図1ないし1477(配列番号1ないし1477)のいずれか1つに示すポリペプチドをコードするヌクレオチド配列
に対して、少なくとも80%の核酸配列同一性を有する単離された核酸。 - 請求項1に記載の核酸を含んでなるベクター。
- ベクターで形質転換された宿主細胞によって認識されるコントロール配列に作用可能に結合している請求項2に記載のベクター。
- 請求項2に記載のベクターを含んでなる宿主細胞。
- 前記細胞がCHO細胞、大腸菌、又は酵母菌である、請求項4に記載の宿主細胞。
- PROポリペプチドの製造方法において、前記PROポリペプチドの発現に適した条件下で請求項5に記載の宿主細胞を培養し、細胞培養物から前記PROポリペプチドを回収することを含んでなる方法。
- (a)図1ないし1477(配列番号1ないし1477)のいずれか1つに示すポリペプチド;又は
(b)図1ないし1477(配列番号1ないし1477)のいずれか1つに示すヌクレオチド配列の完全長コード化領域によってコードされるポリペプチド
に対して少なくとも80%のアミノ酸配列同一性を有する単離されたポリペプチド。 - 異種アミノ酸配列と融合した請求項7に記載のポリペプチドを含んでなるキメラ分子。
- 前記異種アミノ酸配列がエピトープタグ配列又はイムノグロブリンのFc領域である、請求項8に記載のキメラ分子。
- 請求項7に記載のポリペプチドと特異的に結合する抗体。
- 前記抗体がモノクローナル抗体、ヒト化抗体、又は一本鎖抗体である、請求項10に記載の抗体。
- (a)請求項7に記載のポリペプチド、(b)前記ポリペプチドのアゴニスト、(c)前記ポリペプチドのアンタゴニスト、或いは(d)前記ポリペプチドと結合する抗体、を担体と組み合わせてなる組成物。
- 前記担体が製薬的に許容可能な担体である、請求項12に記載の組成物。
- (a)、(b)、(c)又は(d)の治療的有効量を含む、請求項13に記載の組成物。
- 容器;
前記容器上のラベル;並びに
(a)請求項7に記載のポリペプチド、(b)前記ポリペプチドのアゴニスト、(c)前記ポリペプチドのアンタゴニスト、或いは(d)前記ポリペプチドと結合する抗体を含有し、前記容器に含められる組成物を含む製造品であって、前記容器上のラベルによって組成物が免疫関連疾患の治療に用いることが可能であることが示される、製造品。 - 治療の必要がある哺乳動物の免疫関連疾患を治療するための医薬であって、(a)請求項7に記載のポリペプチド、(b)前記ポリペプチドのアゴニスト、(c)前記ポリペプチドのアンタゴニスト、或いは(d)前記ポリペプチドと結合する抗体、の治療的有効量を含んでなる医薬。
- 免疫関連疾患が、全身性紅斑性狼瘡、リウマチ様関節炎、骨関節症、若年性慢性関節炎、脊椎関節症、全身性硬化症、特発性炎症ミオパシー、シェーグレン症候群、全身性血管炎、サルコイドーシス、自己免疫性溶血性貧血、自己免疫性血小板減少、甲状腺炎、真性糖尿病、免疫仲介腎疾患、中枢又は末梢神経系の脱髄疾患、特発性脱髄性多発神経障害、ギラン-バレー症候群、慢性炎症脱随性多発神経障害、肝胆道疾患、感染性又は自己免疫性慢性活動性肝炎、原発性胆汁性肝硬変症、肉芽腫性肝炎、硬化性胆管炎、炎症性腸疾患、グルテン過敏性腸疾患、ウィップル病、自己免疫又は免疫媒介皮膚疾患、水疱性皮膚疾患、多形性紅斑、接触性皮膚炎、乾癬、アレルギー性疾患、喘息、アレルギー性鼻炎、アトピー性皮膚炎、食物過敏症、蕁麻疹、肺の免疫疾患、好球性肺炎、特発性肺線維症、過敏性肺炎、移植関連疾患、移植片拒絶反応、又は移植片対宿主疾患である、請求項16の医薬。
- 図1ないし1477(配列番号1ないし1477)に示すPROポリペプチドの試料中の存在を決定する方法であって、該ポリペプチドを含むと思われる試料を抗PRO抗体に曝露し、前記試料の成分に対する前記抗体の結合を決定することを含んでなる方法。
- 哺乳動物の免疫関連疾患を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、図1ないし1477(配列番号1ないし1477)に示すPROポリペプチドをコードする遺伝子の発現レベルを検出するための手段を含んでなり、コントロール試料と比較して試験試料中における前記遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示されるキット。
- 哺乳動物の免疫関連疾患を診断するためのキットであって、(a)前記哺乳動物から採取した組織細胞の試験試料と、図1ないし1477(配列番号1ないし1477)に示すPROポリペプチドの抗PRO抗体とを接触させるための手段と、(b)抗体と試験試料中のポリペプチドの間の複合体の形成を検出するための手段を含んでなり、前記複合体の形成により、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示されるキット。
- 図1ないし1477(配列番号1ないし1477)に示すPROポリペプチドの活性を阻害する化合物を同定する方法であって、正常に前記ポリペプチドに応答する細胞を(a)前記ポリペプチドと(b)候補化合物とに接触させ、前記細胞の(a)に対する応答性の欠如を測定することを含んでなる方法。
- 図1ないし1477(配列番号1ないし1477)に示すPROポリペプチドをコードする遺伝子の発現を阻害する化合物を同定する方法であって、正常に前記ポリペプチドを発現する細胞を候補化合物と接触させ、前記遺伝子の発現の欠如を測定する方法。
- 前記候補化合物がアンチセンス核酸である、請求項22の方法。
- 図1ないし1477(配列番号1ないし1477)のいずれか1つに示すPROポリペプチドの活性を模倣する化合物を同定する方法であって、正常に前記ポリペプチドへ応答する細胞を候補化合物と接触させ、前記細胞による前記候補化合物への応答性を測定することを含んでなる方法。
- 哺乳動物の免疫反応を刺激する方法において、前記哺乳動物に対し、図1ないし1477(配列番号1ないし1477)のいずれか1つに示すPROポリペプチドのアンタゴニストの有効量を投与し、前記免疫反応を刺激することを含んでなる方法。
- 哺乳動物の炎症性免疫反応を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、図1ないし1477(配列番号1ないし1477)のいずれか1つに示すPROポリペプチドをコードする遺伝子の発現レベルを検出するための手段を含んでなり、コントロール試料と比較して試験試料中における前記遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における炎症性免疫反応の存在が示されるキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42523502P | 2002-11-08 | 2002-11-08 | |
PCT/US2003/035268 WO2004043361A2 (en) | 2002-11-08 | 2003-11-06 | Compositions and methods for the treatment of natural killer cell related diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009273979A Division JP2010099073A (ja) | 2002-11-08 | 2009-12-01 | ナチュラルキラー細胞関連疾患の治療のための組成物と方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006516094A JP2006516094A (ja) | 2006-06-22 |
JP2006516094A5 true JP2006516094A5 (ja) | 2006-12-14 |
Family
ID=32312948
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004551756A Pending JP2006516094A (ja) | 2002-11-08 | 2003-11-06 | ナチュラルキラー細胞関連疾患の治療のための組成物と方法 |
JP2009273979A Pending JP2010099073A (ja) | 2002-11-08 | 2009-12-01 | ナチュラルキラー細胞関連疾患の治療のための組成物と方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009273979A Pending JP2010099073A (ja) | 2002-11-08 | 2009-12-01 | ナチュラルキラー細胞関連疾患の治療のための組成物と方法 |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1581169A4 (ja) |
JP (2) | JP2006516094A (ja) |
AU (2) | AU2003295401B2 (ja) |
CA (1) | CA2503748A1 (ja) |
WO (1) | WO2004043361A2 (ja) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7897575B2 (en) | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
US7482322B2 (en) * | 2003-10-30 | 2009-01-27 | Kazusa Dna Research Institute Foundation | Plexin family-like polypeptide, and uses thereof |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
WO2005115517A2 (en) * | 2004-04-28 | 2005-12-08 | Joslin Diabetes Center, Inc. | Methods of treating diabetes |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
KR100664587B1 (ko) * | 2004-12-22 | 2007-01-04 | 김현기 | 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 이를포함하는 발현 벡터 및 이 벡터로 형질전환된 세포 |
WO2006072946A2 (en) * | 2005-01-04 | 2006-07-13 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
EP1866418A2 (en) | 2005-02-22 | 2007-12-19 | Ceres Inc. | Modulating plant alkaloids |
US8124839B2 (en) | 2005-06-08 | 2012-02-28 | Ceres, Inc. | Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations |
JP2009518048A (ja) * | 2005-12-07 | 2009-05-07 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と軽減のための組成物と方法 |
WO2007128545A2 (en) * | 2006-05-05 | 2007-11-15 | Birgit Ebner | Mac30 gene |
EP2081584A2 (en) * | 2006-10-09 | 2009-07-29 | Government Of The United States Of America As Represented by Secretary of the Dep. of Health and Human Services National Institute of Health | Treatment of inflammation, demyelination and neuronal/axonal loss |
WO2008094510A2 (en) | 2007-01-26 | 2008-08-07 | The Regents Of The University Of Colorado | Methods of modulating immune function |
JP5442208B2 (ja) * | 2007-03-15 | 2014-03-12 | 株式会社日立ハイテクノロジーズ | うつ病の検査方法 |
EP2215108A4 (en) | 2007-10-23 | 2012-07-04 | Univ Colorado | COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING |
WO2009105230A2 (en) | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
WO2010011315A2 (en) * | 2008-07-25 | 2010-01-28 | Viral Genetics, Inc. | Proteins for use in diagnosing and treating infection and disease |
EP2323679A4 (en) * | 2008-07-25 | 2012-08-22 | Univ Colorado | CLIP HEMMER AND METHOD FOR MODULATING THE IMMUNE FUNCTION |
WO2010141999A1 (en) * | 2009-06-12 | 2010-12-16 | The University Of Queensland | Agents and methods for diagnosing and treating ankylosing spondylitis |
IN2012DN03025A (ja) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
US20130028917A1 (en) | 2010-04-15 | 2013-01-31 | Spirogen Developments Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
JP5987053B2 (ja) | 2011-05-12 | 2016-09-06 | ジェネンテック, インコーポレイテッド | フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法 |
AU2012322607B2 (en) | 2011-10-14 | 2017-02-16 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US9359404B2 (en) | 2011-12-01 | 2016-06-07 | Scott & White Healthcare | Methods and products for treating preeclampsia and modulating blood pressure |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
EP2906298B1 (en) | 2012-10-12 | 2018-10-03 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
LT2906253T (lt) | 2012-10-12 | 2018-10-10 | Adc Therapeutics Sa | Pirolobenzodiazepino-anti-psma antikūno konjugatas |
CA2887899C (en) | 2012-10-12 | 2020-03-31 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
EA031585B1 (ru) | 2012-12-21 | 2019-01-31 | Медимьюн Лимитед | Пирролобензодиазепины и их конъюгаты |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
AR096287A1 (es) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados |
CA2904044C (en) | 2013-03-13 | 2020-03-31 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
BR112016012410A2 (pt) | 2013-12-16 | 2017-09-26 | Genentech Inc | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
MX2016007826A (es) | 2013-12-16 | 2017-03-31 | Genentech Inc | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco. |
CN106102835B (zh) | 2014-01-13 | 2020-11-03 | 博格有限责任公司 | 烯醇酶1(eno1)组合物及其用途 |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
CN107108724A (zh) | 2014-09-12 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 半胱氨酸改造抗体和缀合物 |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
CA2968447A1 (en) | 2014-11-25 | 2016-06-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms |
CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
JP6854246B2 (ja) | 2015-06-08 | 2021-04-07 | アーケア ダイアグノスティクス リミテッド | 尿サンプルの分析方法 |
EP3304084B1 (en) | 2015-06-08 | 2022-03-23 | Arquer Diagnostics Limited | Methods and kits |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
KR20200032243A (ko) | 2017-02-08 | 2020-03-25 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
UA127900C2 (uk) | 2017-06-14 | 2024-02-07 | Ейдісі Терапьютікс Са | Схема дозування для введення adc до cd19 |
DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
ES2797848A1 (es) * | 2019-06-03 | 2020-12-03 | Univ Murcia | Metodo in vitro para el diagnostico, pronostico y/o cribado de pacientes susceptibles de sufrir celiaquia |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5681930A (en) * | 1985-12-20 | 1997-10-28 | Bristol-Myers Squibb Company | Anti-oncostatin M monoclonal antibodies |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
KR0154872B1 (ko) | 1987-12-21 | 1998-10-15 | 로버트 에이. 아미테이지 | 발아하는 식물종자의 아크로박테리움 매개된 형질전환 |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
WO1990012585A1 (en) * | 1989-04-10 | 1990-11-01 | Oncogen Limited Partnership | Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m |
DE394538T1 (de) | 1989-04-28 | 1991-04-11 | Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf, De | Hefezellen der schwanniomyces-gattung. |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ZA909842B (en) * | 1989-12-08 | 1991-09-25 | Oncogen | Proteins with oncostatin m activity and process for their preparation |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1993005169A1 (en) * | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
DE69326937T2 (de) | 1993-03-24 | 2000-12-28 | Berlex Biosciences Richmond | Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung |
US5821332A (en) * | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
US5958442A (en) * | 1997-10-24 | 1999-09-28 | Bristol-Myers Squibb Company | Oncostatin M for treating inflammation |
GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
WO2002000677A1 (en) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
IL137419A0 (en) * | 2000-07-20 | 2001-07-24 | Yissum Res Dev Co | Nk cells activating receptors and their therapeutic and diagnostic uses |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
-
2003
- 2003-11-06 JP JP2004551756A patent/JP2006516094A/ja active Pending
- 2003-11-06 WO PCT/US2003/035268 patent/WO2004043361A2/en active Application Filing
- 2003-11-06 EP EP03786587A patent/EP1581169A4/en not_active Withdrawn
- 2003-11-06 EP EP11156084A patent/EP2364716A3/en not_active Withdrawn
- 2003-11-06 CA CA002503748A patent/CA2503748A1/en not_active Abandoned
- 2003-11-06 AU AU2003295401A patent/AU2003295401B2/en not_active Ceased
-
2009
- 2009-12-01 JP JP2009273979A patent/JP2010099073A/ja active Pending
-
2010
- 2010-07-14 AU AU2010202969A patent/AU2010202969A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006516094A5 (ja) | ||
CA2503125A1 (en) | Novel composition and methods for the treatment of immune related diseases | |
JP2005535290A5 (ja) | ||
JP5150488B2 (ja) | Fc領域含有タンパク質を精製する方法 | |
JP2010187677A5 (ja) | ||
CN105504059A (zh) | 白细胞介素-31单克隆抗体 | |
JP2010162016A5 (ja) | ||
JP2010220614A5 (ja) | ||
KR20100102197A (ko) | 항 mif 항체 | |
JP2006521082A5 (ja) | ||
TW200821026A (en) | Arginine wash in protein purification using affinity chromatography | |
EP2748613B1 (en) | Oxmif as a diagnostic marker | |
AU2020453086B2 (en) | Anti-human interleukin 23 monoclonal antibody and application thereof | |
JP4984160B2 (ja) | 抗体の作製方法 | |
CN112920275A (zh) | 可特异性结合sST2的结合蛋白、试剂和试剂盒 | |
CN102232087A (zh) | 修饰的人igf-1/e肽的抗体 | |
JP2006521810A5 (ja) | ||
US10995133B2 (en) | Method for producing antibody | |
US20230384326A1 (en) | Test method and test kit for adult still's disease | |
JP6976566B2 (ja) | イヌアトピー性皮膚炎の治療及び診断のために用いる抗イヌtarc抗体 | |
JP2010029191A5 (ja) | ||
JP2005519590A5 (ja) | ||
JP2006515748A5 (ja) | ||
KR20210049894A (ko) | 항-인간 심근 트로포닌 i 재조합 항체 | |
KR20210055754A (ko) | 항 인간 심근 트로포닌 i의 항체 및 그 사용 |